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digestive decontamination trials performed
by Dr. van Saene and colleagues, previous-
ly published studies on the efficacy of non-
absorbable polyenes for the prevention of
fungal infections in ICU or cancer patients
have not shown clearcut beneficial impact
of this strategy [7, 8, 9, 10].
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The fact that 90% of the placebo-treated
patients did not develop invasive Candida
infection in the study by Garbino et al. [1]
supports our comment that fine tuning of
patient selection criteria may indeed help
to better identify ICU patients who may
benefit from preventive antifungal strate-
gies in future trials. However, in contrast 
to the affirmation of Dr. van Saene and col-
leagues [2], we did not write that “systemic
antifungal prophylaxis will undoubtedly
assist in the future fine tuning of who may
or may not benefit from preventive anti-
fungal strategies,” which would have been
a rather awkward statement.
In recent years several studies have
shown that oral or intravenous prophylaxis
or preemptive therapy with azoles does 
reduce the incidence of systemic yeast
(mainly Candida) infections in trauma,
surgical, and ICU patients [1, 3, 4, 5, 6].
While awaiting the publication of the 
results of the meta-analysis of selective 
